Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden of disease - A population-based study

Abstract

Background: X-linked adrenoleukodystrophy (ALD) is a rare metabolic and neurodegenerative disorder belonging to the group of leukodystrophies, with an estimated incidence around 1:25 000 newborns worldwide, mostly among men. Childhood Cerebral ALD (CCALD) is the most severe form with a poor prognosis if not properly treated during the first years of life. Currently, only allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely available for CCALD treatment. To date, there is a lack of data regarding CCALD epidemiology, natural history, and current management in France. This knowledge is crucial for the development of new therapies such as gene therapies. In this context, the French National Health Data System (SNDS) is a particularly indicated database to collect information meeting these needs. A non-interventional, national, real-life, retrospective study was performed using secondary data from the national ALD registry (LEUKOFRANCE) and SNDS. CCALD patients detected between 2009 and 2018 and successfully matched between LEUKOFRANCE and SNDS were included in this study. Index date was defined as the first CCALD event detected during study period. Subgroups of patients with sufficient follow-up (6 months) and history (1 year) available around index date were analyzed to assess CCALD burden and natural history.

Results: 52 patients were included into the matched cohort. Median annual incidence of CCALD was estimated at 4 patients. Median age at CCALD diagnosis was 7.0 years. Among patients without allo-HSCT, five-year overall survival was 66.6%, with 93.3% of them presenting at least one CCALD symptom and 62.1% presenting a least one major functional disability (MFD). Among patients with allo-HSCT, five-year overall survival was 94.4%, with only 11.1% of patients presenting CCALD symptoms, and 16.7% of presenting a MFD. Mean annualized costs were almost twice as important among patients without allo-HSCT, with 49,211€, 23,117€, respectively. Costs were almost exclusively represented by hospitalizations.

Conclusions: To the best of our knowledge, this is the most up to date study analyzing CCALD epidemiology, clinical and economic burden in France. The necessity of a precocious management with HSCT highlight the potential benefits of including an expanded screening program among newborns, coupled with family screenings when a mutation is detected.

Keywords: Adrenoleukodystrophy; CCALD; Care management; Claims; Epidemiology; HSCT; Health cost; Neurodegenerative diseases; Registry; SNDS.

Fig. 1

Patient Disposition (N = 52) ICD-10 ALD codes (E71.3, G13, G31.8, G31.9, G37.8, G37.9, G53.8, G64, G94, G95, G99) ALD events: hospitalization or Long Duration Disease record with ICD-10 ALD codes

Fig. 2

MFD-free Survival (months) from CCALD Diagnosis for Patients with and without HSCT - Kaplan-Meier (N = 47) MFD gathers: loss of communication, use of wheelchair, incontinence, blindness, use of enteral feeding (nasogastric/gastrostomy) and loss of movement. HSCT only refers to allogenic transplantations

Fig. 3

Overall Survival (months) from CCALD Diagnosis for Patients with and without HSCT - Kaplan-Meier (N = 47) HSCT only refers to allogenic transplantations

Fig. 4

Mean annualized Costs (€) for patients with and without HSCT during Study Period (N = 48) HH: home hospitalization Other costs gather medical devices, laboratory tests, procedures, medications and transportations HSCT only refers to allogenic transplantations